Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [0]
- Comments [0]
- Validations
- Western blot [1]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- RA0152 - Provider product page
- Provider
- Oursmab
- Product name
- Cabiralizumab (Biosimilar Reference Antibody) (CSF1R)
- Antibody type
- Monoclonal
- Description
- Cabiralizumab is an investigational humanized monoclonal antibody designed for cancer therapy, specifically functioning as an inhibitor of the colony-stimulating factor 1 receptor (CSF-1R). It was developed with the primary goal of modulating the tumor microenvironment by targeting immunosuppressive tumor-associated macrophages (TAMs). Clinical trials explored its use, particularly in combination with checkpoint inhibitors such as nivolumab (anti-PD-1), for advanced solid tumors including pancreatic cancer, renal cell carcinoma, and non-small cell lung cancer. While early-phase studies demonstrated some potential for synergistic activity, its overall development has been limited, and the drug has not progressed to widespread regulatory approval.
- Reactivity
- Human
- Isotype
- IgG
- Vial size
- 100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
- Concentration
- Bottled at the concentration indicated on the vial.
- Storage
- Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
No comments: Submit comment
Supportive validation
- Submitted by
- Oursmab (provider)
- Main image
- Experimental details
- Cabiralizumab (Biosimilar Reference Antibody) (CSF1R)-RA0152-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.
Supportive validation
- Submitted by
- Oursmab (provider)
- Main image
- Experimental details
- ELISA plate pre-coated Antigen protein, can bind Cabiralizumab (Biosimilar Reference Antibody) (CSF1R)-RA0152 in a linear range of 0.18-125 ng/mL.
